NPT520-34

NPT520-34 is an orally bioavailable, blood-brain barrier penetrating small molecule in clinical development for the treatment of neurodegenerative disorders, primarily Parkinson's disease and amyotrophic lateral sclerosis (ALS)[1][2][3][4][5][6]. It acts as an antagonist of toll-like receptor 2 (TLR2), a pattern-recognition innate immune receptor expressed on neurons and glial cells[2]. By antagonizing TLR2, NPT520-34 reduces astrocytic and microglial markers of neuroinflammation and facilitates the clearance of misfolded protein aggregates such as alpha-synuclein, superoxide dismutase 1 (SOD1), and beta-amyloid[1][4][7][8]. Preclinical studies have shown that it lowers toxic protein accumulation, reduces inflammation in animal models of Parkinson’s disease, ALS, and Alzheimer’s disease, preserves dopamine signaling in the brain, improves motor function in mice models of Parkinson’s disease, and prolongs survival in ALS mouse models[4][5][6]. The drug has received orphan drug designation from the FDA for ALS[3][7].